Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade
Importance The anti–programmed cell death protein 1 (PD-1) antibody pembrolizumab is
approved by the US Food and Drug Administration for the treatment of microsatellite
instability–high (MSI-H) or mismatch repair–deficient (dMMR) solid tumors, but the
prevalence of MSI-H/dMMR prostate cancer and the clinical utility of immune checkpoint
blockade in this disease subset are unknown. Objective To define the prevalence of MSI-
H/dMMR prostate cancer and the clinical benefit of anti–PD-1/programmed cell death 1 …
approved by the US Food and Drug Administration for the treatment of microsatellite
instability–high (MSI-H) or mismatch repair–deficient (dMMR) solid tumors, but the
prevalence of MSI-H/dMMR prostate cancer and the clinical utility of immune checkpoint
blockade in this disease subset are unknown. Objective To define the prevalence of MSI-
H/dMMR prostate cancer and the clinical benefit of anti–PD-1/programmed cell death 1 …
